New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 16, 2012
08:36 EDTRGRXRegeneRx completes license agreement for development of RegeneRx products
RegeneRx announced that it has entered into a licensing agreement with Lee's Pharmaceutical Limited for the license to Lee's of RegeneRx's Thymosin Beta 4-based products, including the company's RGN-259, RGN-352 and RGN-137 product candidates, in China and Taiwan. Lee's previously paid RegeneRx $200,000 upon signing of a term sheet and will pay RegeneRx an additional $200,000 with the completion of this license agreement. The terms of the deal include aggregate potential milestone payments of up to $3.6M and royalties ranging from low double digit to high single digit royalties on commercial sales. RegeneRx also has the right to exclusively license any improvements made by Lee's to RegeneRx's products outside of the licensed territory.
News For RGRX From The Last 14 Days
Check below for free stories on RGRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 21, 2014
12:39 EDTRGRXRegeneRx receives notice of allowance for U.S. patent for treatment of stroke
RegeneRx Biopharmaceuticals announced that it has received a Notice of Allowance for a second U.S. patent for treating central nervous system injuries and disorders using Thymosin beta 4 to regenerate damaged tissue. In this case, the patent will be for the treatment of patients suffering a stroke. Researchers at the Henry Ford Hospital in Detroit, Michigan, discovered Tβ4ís effects in animal studies performed under a Material Transfer Agreement between the Institution and RegeneRx. RegeneRx has received a license to the intellectual property. The patent will expire in 2026.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use